Samsung Biologics

104 articles about Samsung Biologics

• Samsung Biologics signs additional development and manufacturing agreement with STCube

  7/12/2020

  Samsung Biologics has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate.

• Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020

  6/8/2020

  Samsung Biologics announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week.

• Samsung Biologics Expands Business Continuity Excellence with Additional ISO 22301 Certification

  5/19/2020

  Samsung Biologics announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business continuity management system.

• Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)

  4/23/2020

  Samsung Biologics and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018.

• Samsung Biologics Earnings to Beat Consensus Again, Continues to Sign New Projects with Enhanced Virtual Support

  4/22/2020

  Samsung Biologics announced Q1 earnings results on Monday, April 20th. The company posted consolidated sales of 207.2 billion Korean Won, operating profit of 62.6 billion Korean Won, and net income of 39.1 billion Korean Won.

• Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment

  4/10/2020

  Samsung Biologics and Vir Biotechnology, Inc. announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal antibody program..

• 

  Biopharma Update on the Novel Coronavirus: April 10

  4/10/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.

• Samsung Biologics named Champion in 2020 CMO Leadership Awards

  4/8/2020

  Samsung Biologics announced that it has been awarded the 2020 CMO Leadership Awards for its excellence in the Capabilities, Compatibility, Quality, Reliability, and Service categories across Big Pharma and Overall, making this the seventh consecutive year the company has received this distinction.

• Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment

  4/6/2020

  Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next generation therapeutic antibody candidate to treat oncology and neovascular disorders.

• 

  BioSpace Movers & Shakers, April 3

  4/3/2020

  Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.

• Samsung Biologics expands leadership for CDO business

  3/30/2020

  Samsung Biologics (207940.KS) has appointed Eun Young Yang as vice president of business development for the company's expanded CDO (contract development organization) business. "Eun is one

• Samsung Biologics Adds Greater Expertise and Diversity to Its Board

  3/20/2020

  Samsung Biologics (207940.KS) announced the appointment and expansion of its board of directors at its 9 th annual general meeting of shareholders that took place on March 20 th . In the course of expanding its business model from a contract manufacturing (CMO) company to development (CDO) and research (CRO) services, Samsung

• Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate

  3/17/2020

  Samsung Biologics entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer's disease, which are all currently incurable.

• Samsung Biologics Reports 64% Jump in FY19 Earnings, Sees Global Expansion in 2020

  2/4/2020

  Samsung Biologics, a pharmaceutical Contract Manufacturing Organization, recorded high for the fiscal year 2019, reporting 30.9% growth in sales at 701.6 billion won, and 64.6% growth in operating profit at 91.7 billion won compared to the previous year.

• Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO

  11/14/2019

  Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management.

• Samsung Biologics and Ichnos Sciences Announce Agreement for Manufacture of ISB 830

  11/4/2019

  Based on an entirely new mechanism of action, ISB 830 has the potential to treat a range of autoimmune diseases beyond atopic dermatitis

• Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application

  8/12/2019

  Cients may choose from a more diversified portfolio of manufacturing options.

• Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

  7/31/2019

  Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals.

• Samsung BioLogics Enters New Era with "First-of-its-kind" Client-Centric CMO Deal

  6/5/2019

  Samsung BioLogics recently entered a new era by signing a "first of its kind" deal with a US biopharmaceutical company valued at $7.8 million US through 2020.

• CytoDyn and Samsung BioLogics Formalize Manufacturing Partnership

  5/30/2019

  CytoDyn Inc., a late stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at the Samsung BioLogics Songdo headquarters for an official signing ceremony of the manufacturing agreement with Samsung BioLogics that was previously announced on April 2, 2019.